PhaseBio Pharmaceuticals, Inc. (PHAS)
R&D Expense Growth
-99.86%
Fiscal year · Period ending:
PHAS R&D Expense Growth
Latest reported-99.86%period ending
Latest reported-99.86%period ending
PHAS FY R&D Growth (YoY) (0.00% → -99.86%)
Latest values, visible window
High-resolution chart · PNG
PHAS r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -99.8584% | |
| 133.2115% | |
| 100.0065% | |
| 148.8728% | |
| -15.808% | |
| 0% |